Send me a link:

*Text messaging rates may apply.

 Dow Up0.13% Nasdaq Down0.10%

Franklin Biotechnology Discovery R6 (FRBRX)

143.89 Down 0.98(0.68%) Jul 28

Profile as of Jun 29, 2014Get Profile for:
Franklin Biotechnology Discovery R6
Franklin Strategic SeriesOne Franklin ParkwaySan Mateo, CA 94403-1906
Map
Phone: 800-632-2301
Fund Overview 
Category:Health
Fund Family:Franklin Templeton Investments
Net Assets:1.45B
Year-to-Date Return:10.11%
Yield:0.00%
Morningstar Rating:4 stars
Fund Inception Date:May 1, 2013
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Evan S. McCulloch
Lead Manager since Sep 15, 1997
Evan McCulloch is a vice president and portfolio manager for Franklin Advisers, Inc. He is the portfolio manager of the Franklin Biotechnology Discovery Fund. Mr. McCulloch also specializes in research analysis of the health care industry; including biotechnology, pharmaceuticals, health care information systems/internet, and health care providers. Mr. McCulloch joined Franklin Templeton Investments in 1992. He was co-manager of the Franklin Biotechnology Discovery Fund since its inception in 1997 and lead manager of the fund since November 2000. Mr. McCulloch received a bachelor's degree in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) and a member of the Association for Investment Management and Research (AIMR) and the Security Analysts of San Francisco (SASF).
Investment Information 
Min Initial Investment:0
Min Initial Investment, IRA:N/A
Min Initial Investment, AIP:N/A
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:N/A
FRBRX can be purchased from 6 brokerages.

Fund Summary 
The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 15, 2013) : 0.00
Annual Holdings Turnover (Jul 23, 2014) : 48.70%
Average for Category:53.49%
Fees & Expenses 
ExpenseFRBRXCategory Avg
Annual Report Expense Ratio (net):0.63%1.38%
Prospectus Net Expense Ratio:0.71%N/A
Prospectus Gross Expense Ratio:0.72%N/A
Max 12b1 Fee:N/AN/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.37%
3 Yr Expense Projection*:229655
5 Yr Expense Projection*:4001,028
10 Yr Expense Projection*:8942,020
* Per $10,000 invested